[go: up one dir, main page]

JOP20200156A1 - إيسكيتامين لعلاج الاكتئاب - Google Patents

إيسكيتامين لعلاج الاكتئاب

Info

Publication number
JOP20200156A1
JOP20200156A1 JOP/2020/0156A JOP20200156A JOP20200156A1 JO P20200156 A1 JOP20200156 A1 JO P20200156A1 JO P20200156 A JOP20200156 A JO P20200156A JO P20200156 A1 JOP20200156 A1 JO P20200156A1
Authority
JO
Jordan
Prior art keywords
esketamine
depression
treatment
effective amount
patient
Prior art date
Application number
JOP/2020/0156A
Other languages
English (en)
Inventor
Carla Canuso
Ewa Wajs
Jaskaran Singh
David Wood Hough
Rachel Ochs-Ross
Wayne Drevets
Honglan Li
Peter Zannikos
Adam Janik
Ella Daly
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of JOP20200156A1 publication Critical patent/JOP20200156A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

يوفر الاختراع الحالي طرقًا للحفاظ على هدأة أو استجابة مستقرة من جانب مريض يعاني من الاكتئاب بعد إعطاء كمية فعالة علاجيًا من إيسكيتامين خلال مرحلة الإعطاء الأولي، وتتألف من الاستمرار في إعطاء كمية فعالة علاجيًا من إيسكيتامين لمدة خمسة أشهر على الأقل خلال مرحلة الإعطاء اللاحق. ويوفر الاختراع الحالي أيضًا طرقًا للعلاج طويل الأجل للاكتئاب لدى مريض، وتتألف من إعطاء المريض الذي يحتاج إلى العلاج كمية فعالة علاجيًا من إيسكيتامين ثبت طبيًا أنها آمنة وفعالة لمدة ستة أشهر على الأقل. وفي بعض النماذج التطبيقية، يكون الاكتئاب عبارة عن اضطراب اكتئابي كبير أو اكتئاب مقاوم للعلاج. الشكل 1
JOP/2020/0156A 2017-12-22 2018-12-18 إيسكيتامين لعلاج الاكتئاب JOP20200156A1 (ar)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762609504P 2017-12-22 2017-12-22
US201862663219P 2018-04-26 2018-04-26
US201862663206P 2018-04-26 2018-04-26
US201862667406P 2018-05-04 2018-05-04
US201862675846P 2018-05-24 2018-05-24
US201862755905P 2018-11-05 2018-11-05
PCT/US2018/066143 WO2019126108A1 (en) 2017-12-22 2018-12-18 Esketamine for the treatment of depression

Publications (1)

Publication Number Publication Date
JOP20200156A1 true JOP20200156A1 (ar) 2022-10-30

Family

ID=65003585

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0156A JOP20200156A1 (ar) 2017-12-22 2018-12-18 إيسكيتامين لعلاج الاكتئاب

Country Status (16)

Country Link
US (3) US11707440B2 (ar)
EP (1) EP3501542B1 (ar)
JP (2) JP7807870B2 (ar)
KR (2) KR20240011237A (ar)
CN (2) CN112423789A (ar)
AU (2) AU2018282466A1 (ar)
BR (1) BR112020012473A2 (ar)
CA (1) CA3086478A1 (ar)
IL (2) IL275482B1 (ar)
JO (1) JOP20200156A1 (ar)
MA (1) MA47719A (ar)
MX (2) MX2020006650A (ar)
PH (1) PH12020500555A1 (ar)
SG (1) SG11202005896WA (ar)
TW (2) TWI843711B (ar)
WO (1) WO2019126108A1 (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022972B1 (pt) 2013-03-15 2023-02-14 Janssen Pharmaceutica Nv Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN112423789A (zh) 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3813807A1 (en) 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
CA3113198A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
PL3976012T3 (pl) * 2019-05-31 2024-06-24 Afyx Therapeutics A/S Donosowe podawanie ketaminy pacjentom z klasterowym bólem głowy
US20220151955A1 (en) * 2019-08-05 2022-05-19 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
EP4021432A4 (en) * 2019-08-28 2023-08-16 Janssen Pharmaceuticals, Inc. ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
CA3153856A1 (en) * 2019-09-13 2021-03-18 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
JP2023538901A (ja) * 2020-08-18 2023-09-12 オークウッド ラボラトリーズ，エル．エル．シー． ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
WO2022087383A1 (en) * 2020-10-22 2022-04-28 Tonix Pharmaceuticals Holding Corp. Randomization honoring methods to assess the significance of interventions on outcomes in disorders
EP4494634A4 (en) * 2022-04-26 2025-07-23 Yichang Humanwell Pharmaceutical Co Ltd LIQUID PREPARATION OF ESKETAMINE AND ITS USE
WO2024201274A1 (en) * 2023-03-24 2024-10-03 Janssen Pharmaceutica Nv Esketamine for use in the treatment of depression
WO2024263816A2 (en) * 2023-06-21 2024-12-26 Cristcot Llc Development and validation of the hemorrhoid disease symptom impact measure
WO2025106879A1 (en) * 2023-11-15 2025-05-22 Gilgamesh Pharmaceuticals, Inc. Methods of treating psychiatric disorders or pain using (r)-2-(4-fluorophenyl)-2-(methylamino)cyclohexan-1-one or pharmaceutically acceptable salts thereof
US20250241873A1 (en) * 2024-01-26 2025-07-31 Inesket Llc Ketamine nasal spray formulation and methods of use

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10025A (en) 1853-09-20 Improvement in turbines
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
WO1996025925A1 (en) 1995-02-24 1996-08-29 Weg Stuart L Nasal and ocular administration of ketamine to manage pain and for detoxification
WO1997007750A1 (en) 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
ID29632A (id) 1998-07-24 2001-09-06 Seo Hong Yoo Pembuatan bentuk-bentuk dosis larutan bening berair dengan asam-asam empedu
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
WO2002024116A1 (en) 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
ATE432697T1 (de) 2002-11-18 2009-06-15 Yaupon Therapeutics Inc Analgetische verwendung von (s)-norketamin
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
JP5026411B2 (ja) 2005-06-01 2012-09-12 エスエイチエル グループ エービー 薬物送達装置
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20070256688A1 (en) 2006-04-21 2007-11-08 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
BRPI0711872A2 (pt) 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
ES2560676T3 (es) 2010-06-15 2016-02-22 Grünenthal GmbH Combinación farmacéutica para el tratamiento del dolor
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
EP2766339B1 (en) 2011-10-14 2021-06-09 The United States Of America, as represented by the Secretary, Department of Health & Human Services The use of (2r, 6r)-hydroxynorketamine and other stereoisomeric hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
MX354547B (es) 2011-11-14 2018-03-09 Alfasigma Spa Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión.
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
KR20140136982A (ko) * 2012-03-12 2014-12-01 얀센 파마슈티카 엔.브이. 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
US20140057988A1 (en) 2012-08-23 2014-02-27 Stuart WEG Anxiolytic composition, formulation and method of use
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
MX370506B (es) 2013-04-12 2019-12-16 Icahn School Med Mount Sinai Método para tratar trastorno de estrés post-traumático.
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
CA2936809A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
HUE051264T2 (hu) 2014-04-17 2021-03-01 Develco Pharma Schweiz Ag Ketamin orális dózisformája
PE20171642A1 (es) 2014-05-04 2017-11-09 Firmenich & Cie Alimentos y bebidas saborizados
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
JP6545788B2 (ja) * 2014-08-13 2019-07-17 ヤンセン ファーマシューティカ エヌ．ベー． うつ病の治療方法
CN107208133A (zh) * 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
US20180015054A1 (en) 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
HK1248578A1 (zh) 2015-06-27 2018-10-19 Shenox Pharmaceuticals, Llc 氯胺酮透皮递送系统
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
CN112423789A (zh) 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮

Also Published As

Publication number Publication date
RU2020123893A (ru) 2022-01-24
MA47719A (fr) 2020-01-15
BR112020012473A2 (pt) 2020-11-24
PH12020500555A1 (en) 2021-05-17
MX2020006650A (es) 2020-11-06
US20240000728A1 (en) 2024-01-04
JP2021506924A (ja) 2021-02-22
TW201940162A (zh) 2019-10-16
JP7807870B2 (ja) 2026-01-28
CN117531017A (zh) 2024-02-09
KR20240011237A (ko) 2024-01-25
NZ765616A (en) 2024-12-20
MX2023012450A (es) 2023-10-31
IL319020A (en) 2025-04-01
JP2024001204A (ja) 2024-01-09
US20250332121A1 (en) 2025-10-30
TWI843711B (zh) 2024-06-01
TW202415363A (zh) 2024-04-16
WO2019126108A1 (en) 2019-06-27
IL275482B1 (en) 2025-03-01
RU2020123893A3 (ar) 2022-04-29
EP3501542A1 (en) 2019-06-26
AU2024227438A1 (en) 2024-11-07
IL275482A (en) 2020-08-31
US20210386688A1 (en) 2021-12-16
CN112423789A (zh) 2021-02-26
AU2018282466A1 (en) 2019-07-11
SG11202005896WA (en) 2020-07-29
CA3086478A1 (en) 2019-06-27
US11707440B2 (en) 2023-07-25
EP3501542B1 (en) 2026-01-28
KR20200113197A (ko) 2020-10-06

Similar Documents

Publication Publication Date Title
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
MX2024010140A (es) Nuevos metodos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CO2018006358A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2017005875A (es) Metodos para tratar enfermedades oculares.
EP4403213A3 (en) Methods for reducing cardiovascular risk
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
UA111312C2 (uk) Спосіб лікування гострого коронарного синдрому без елевації сегмента st у пацієнтів з ішемічною хворобою серця та метаболічним синдромом, що перенесли перкутанну транслюмінарну коронарну ангіопластику
EA202191612A1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
ZA202102913B (en) Dosage regime
AR114013A1 (es) Esketamina para el tratamiento de la depresión
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
UA116484U (uk) Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
UA103788U (ru) Способ лечения острого коронарного синдрома без подъема сегмента st у пациентов с ишемической болезнью сердца и метаболическим синдромом, перенесших перкутанную транслюминарную коронарную ангиопластику
UA114639U (xx) Спосіб лікування вторинних кардіоміопатій у дітей та підлітків на фоні синдрому вегетативної дисфункції
RU2013139670A (ru) Применение комбинации ингибитора ангиотензин-превращающего фермента и гормона эпифиза для лечения ишемической болезни сердца у пожилых больных